Cargando…
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs
Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/ https://www.ncbi.nlm.nih.gov/pubmed/30935099 http://dx.doi.org/10.3390/ijms20071607 |
_version_ | 1783413337841729536 |
---|---|
author | Capalbo, Carlo Scafetta, Giorgia Filetti, Marco Marchetti, Paolo Bartolazzi, Armando |
author_facet | Capalbo, Carlo Scafetta, Giorgia Filetti, Marco Marchetti, Paolo Bartolazzi, Armando |
author_sort | Capalbo, Carlo |
collection | PubMed |
description | Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered. The retrospective immuno-phenotypic analysis performed on the original tumor biopsies allowed for the identification of a specific “galectin signature”, which strongly correlated with tumor responsiveness to anti PD-1 immunotherapy. We observed that the large majority of patients (about 90%) with high galectin-3 tumor expression (score 3+) showed an early and dramatic progression of the disease after three cycles of treatments. In contrast, all patients with negative or low/intermediate expression of galectin-3 in tumor cells showed an early and durable objective response to pembrolizumab, indicating galectin-3 as an interesting predictive marker of tumor responsiveness. The galectin-3 signature, at least in NSCLCs, promises a better selection of patient candidates for immunotherapy, reducing unnecessary treatment exposures and social costs. A large multicenter study is ongoing to validate this finding. |
format | Online Article Text |
id | pubmed-6479404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64794042019-04-29 Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs Capalbo, Carlo Scafetta, Giorgia Filetti, Marco Marchetti, Paolo Bartolazzi, Armando Int J Mol Sci Communication Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking. These markers need to be urgently identified for a better selection of patients that can be candidates for immunotherapy. In this pilot study, a cohort of 34 consecutive patients bearing programmed death-ligand 1 (PD-L1)-positive non-small cell lung carcinoma (NSCLC), treated with pembrolizumab, was considered. The retrospective immuno-phenotypic analysis performed on the original tumor biopsies allowed for the identification of a specific “galectin signature”, which strongly correlated with tumor responsiveness to anti PD-1 immunotherapy. We observed that the large majority of patients (about 90%) with high galectin-3 tumor expression (score 3+) showed an early and dramatic progression of the disease after three cycles of treatments. In contrast, all patients with negative or low/intermediate expression of galectin-3 in tumor cells showed an early and durable objective response to pembrolizumab, indicating galectin-3 as an interesting predictive marker of tumor responsiveness. The galectin-3 signature, at least in NSCLCs, promises a better selection of patient candidates for immunotherapy, reducing unnecessary treatment exposures and social costs. A large multicenter study is ongoing to validate this finding. MDPI 2019-03-31 /pmc/articles/PMC6479404/ /pubmed/30935099 http://dx.doi.org/10.3390/ijms20071607 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Capalbo, Carlo Scafetta, Giorgia Filetti, Marco Marchetti, Paolo Bartolazzi, Armando Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title_full | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title_fullStr | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title_full_unstemmed | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title_short | Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs |
title_sort | predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in nsclcs |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479404/ https://www.ncbi.nlm.nih.gov/pubmed/30935099 http://dx.doi.org/10.3390/ijms20071607 |
work_keys_str_mv | AT capalbocarlo predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs AT scafettagiorgia predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs AT filettimarco predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs AT marchettipaolo predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs AT bartolazziarmando predictivebiomarkersforcheckpointinhibitorbasedimmunotherapythegalectin3signatureinnsclcs |